No Data
CARsgen to Present Zevor-cel, CT071 and CT0590 at ASH 2024 Annual Congress
CARsgen U.S. Clinical Holds Lifted by FDA
[Hong Kong Stock Connect] KPC Pharmaceuticals (02171) FDA lifts the US clinical trial suspension of Zovokioran injection and CT071.
Jingu Financial News | Keji Pharmaceutical (02171) announced that the Food and Drug Administration (FDA) of the usa has lifted the clinical trial suspension in the United States for Zevorcel Injection (zevor-cel, CT053, a self-targeting BCMA CAR-T cell product), Saturiucle Injection (satri-cel, CT041, a self-targeting Claudin18.2 CAR-T cell product), and CT071 (a self-targeting GPRC5D CAR-T cell product). The clinical trial suspension is related to 202.
SciClone Pharmaceuticals (02171.HK): FDA has lifted the U.S. clinical trial suspension on Zejovir Olinsa injection, ShuRui Olinsa injection, and CT071.
格隆汇 November 1st, Keji Pharmaceuticals-B (02171.HK) announced that the Food and Drug Administration (FDA) of the United States has lifted the clinical trial suspension for Zevorcere Injection (zevor-cel, CT053, an autologous CAR-T cell product targeting BCMA), Satricere Injection (satri-cel, CT041, an autologous CAR-T cell product targeting Claudin18.2), and CT071 (an autologous CAR-T cell product targeting GPRC5D) in the United States.
Hong Kong stocks are active | Some pharmaceutical stocks rose in early trading, as the national medical insurance negotiations are expected to start soon. Institutions stated that there will be a high concentration of catalytic events in the sector in the
Some pharmaceutical stocks rose in the morning session. As of the time of publication, Remegen (09995) rose by 8.73% to HKD 15.7; SciClone Pharmaceuticals-B (02171) rose by 6.47% to HKD 15.7; Sino Biopharmaceutical-B (01952) rose by 2.11% to HKD 31.5; Fosun Pharma (02196) rose by 3.7% to HKD 15.12.
Express News | National Medical Products Administration: Deploys pilot work on segmented production reform of biological products.
No Data
No Data